25D-NBOMe

Discovery

The NBOMe series of phenethylamines originated in academic research at the Free University of Berlin, where Ralf Heim first synthesized N-(2-methoxybenzyl)-substituted phenethylamines as pharmacological tools around 2000.citation needed The parent compound — 2C-D — had been described earlier by Alexander Shulgin in PiHKAL (1991), where he noted its mild psychedelic effects and nicknamed it "pharmacological tofu" for its utility as a baseline phenethylamine.citation needed Michael Braden's 2007 doctoral work in the Nichols laboratory at Purdue University demonstrated that the N-(2-methoxybenzyl) modification converted moderate-potency 2C compounds into some of the most potent serotonergic agonists then known.^[7]

Emergence in drug supply

NBOMe compounds appeared on online research chemical markets beginning around 2010, distributed primarily on blotter paper visually indistinguishable from LSD.^[8][9] Multiple variants circulated under class-level street names including "N-bomb," "Smiles," and "Solaris." 25D-NBOMe was first analytically confirmed from seized blotter papers by Zuba and Sekuła in 2013.^[3]

Regulatory response

The proliferation of NBOMe compounds prompted rapid scheduling actions. The United States placed 25I-NBOMe, 25B-NBOMe, and 25C-NBOMe into Schedule I in November 2015;^[10] 25D-NBOMe was not named but remains subject to the Federal Analogue Act. The United Kingdom classified NBOMe compounds as Class A following a Temporary Class Drug Order in June 2013.^[11]

Structural class

25D-NBOMe belongs to the NBOMe (N-(2-methoxybenzyl)) subclass of substituted phenethylamines. Its parent compound is 2C-D (2,5-dimethoxy-4-methylphenethylamine), a phenethylamine psychedelic first described by Alexander Shulgin.citation needed The structural transformation from 2C-D to 25D-NBOMe involves appending a 2-methoxybenzyl group to the primary amine nitrogen — a modification that dramatically increases binding strength at the 5-HT₂A receptor by enabling additional contacts with extracellular loop regions.^[8][12]

Molecular properties

The molecule comprises a 2,5-dimethoxy-4-methylphenethylamine core — the 2C-D scaffold — with a 2-methoxybenzyl group bonded to the amine nitrogen. Three methoxy groups and one methyl group decorate the aromatic rings, giving the compound moderate lipophilicity. The hydrochloride salt is the form typically encountered in analytical seizure reports and on blotter preparations.^[3]

Stereochemistry

25D-NBOMe lacks a chirality center. Nitrogen inversion renders the amine configurationally labile, so the compound exists as a single achiral entity. Stereoisomer considerations do not apply.

Mechanism of action

25D-NBOMe activates the serotonin 5-HT₂A receptor as a full agonist — the same molecular target responsible for the effects of classical psychedelics like LSD and psilocybin.^[1] The N-(2-methoxybenzyl) group attached to the 2C-D scaffold dramatically increases binding strength at this receptor, producing psychedelic effects at microgram-level doses.^[8][1] The compound also activates 5-HT₂C receptors with potency comparable to LSD,^[1] while showing very low activity at 5-HT₁A.^[1][9]

Unlike classical psychedelics, 25D-NBOMe produces measurable changes in the brain's dopamine reward circuitry. In the only study conducted specifically on this compound, Lee and colleagues demonstrated that 25D-NBOMe increased dopamine release in the nucleus accumbens of rats and produced self-administration and conditioned place preference — behavioral markers of reinforcing potential.^[4] These dopaminergic effects distinguish NBOMe compounds from classical psychedelics, which generally lack reward-circuit activation.

NBOMe compounds as a class also show affinity at adrenergic, dopamine, and histamine receptors,^[13] though specific binding data at these secondary targets have not been published for 25D-NBOMe. Interactions with monoamine transporters occur only at concentrations far above psychedelic doses, confirming a hallucinogenic rather than stimulant mechanism.^[1]

Pharmacokinetics

No human pharmacokinetic studies exist for 25D-NBOMe. All parameters are inferred from structurally similar NBOMe compounds and limited user reports.

Sublingual or buccal administration is the standard route — oral ingestion is inactive or very weakly active due to breakdown in the gut and extensive first-pass liver metabolism.^[8] Onset occurs 20–40 minutes after sublingual placement. A single indexed user report of buccal administration at 1,600 µg documented onset at approximately 10 minutes, peak effects at approximately 50 minutes, and a total duration of approximately 8 hours.^[14] Class-level data suggest peak effects at 1–2 hours and total duration of 4–8 hours.^[9]

Based on studies of related NBOMe compounds, metabolism proceeds primarily through removal of methoxy groups from the aromatic rings, with secondary hydroxylation pathways.^[15] Metabolites undergo further processing before urinary excretion.^[16] Plasma half-life, bioavailability, and protein binding have not been determined for 25D-NBOMe in any species.

Where it acts

25D-NBOMe's primary target — the 5-HT₂A receptor — is densely expressed on pyramidal neurons in the prefrontal cortex and association cortices.^[17][8] Activation of these receptors increases glutamate release, disrupts thalamic sensory filtering, and shifts the brain toward greater global connectivity at the expense of organized network function.^[17] This produces the characteristic psychedelic signature: dissolution of the default mode network, increased neural signal complexity, and the perceptual fluidity that users experience as visual and cognitive distortion.

The dopaminergic activity documented by Lee and colleagues — increased dopamine release in the nucleus accumbens^[4] — adds a reward-circuit dimension absent from classical psychedelics. This dual serotonergic-dopaminergic action may explain the compound's reinforcing properties and could shape the subjective experience in ways not captured by models built on purely serotonergic compounds.

Theoretical frameworks

The REBUS model (Relaxed Beliefs Under Psychedelics) proposes that psychedelics flatten the brain's belief hierarchy, allowing bottom-up sensory signals to override top-down expectations.citation needed As a potent 5-HT₂A agonist, 25D-NBOMe would be expected to produce this effect — resulting in the perceptual novelty and conceptual flexibility typical of the psychedelic state. Whether the compound also drives structural neuroplasticity (new dendritic growth and synapse formation), as demonstrated for other serotonergic psychedelics, has not been tested.citation needed

Toxicity

No lethal dose has been established for 25D-NBOMe in any species, and no therapeutic index can be calculated. The margin between a psychedelic dose and a potentially dangerous dose is unknown. safety citation needed

• Rapid heart rate, high blood pressure, and dangerously elevated body temperature
• Seizures and extreme agitation
• Muscle breakdown with secondary kidney injury
• Blood clotting dysfunction and metabolic crisis
• Multiple organ failure

Multiple deaths have been attributed to 25I-NBOMe,^[19] 25B-NBOMe,^[20] and 25C-NBOMe.^[21] No fatality has been attributed solely to 25D-NBOMe, though it was found as a component of mixed-NBOMe blotter in a fatality case.^[22]

Psychological risks

No controlled studies of the psychological effects of 25D-NBOMe have been conducted. Class-level risks for NBOMe compounds include^[8][9]:

• Acute psychological distress: anxiety, paranoia, and agitation at recreational doses; at high doses, extreme agitation and uncontrollable behavior
• Psychotic episodes: delusions and disorganized behavior reported for 25I-NBOMe and 25C-NBOMe; no 25D-NBOMe-specific case reports exist
• HPPD: No cases of Hallucinogen Persisting Perception Disorder have been attributed specifically to 25D-NBOMe, though HPPD is documented for the class

The single available user report (1,600 µg buccal) described the mental space as tranquil but noted significant physical distress from cardiovascular effects.^[14]

Tolerance & dependence

Tolerance develops rapidly through 5-HT₂A downregulation following exposure.^[5] Cross-tolerance is expected with LSD, psilocybin, 2C-series compounds, and DOx compounds — all of which act through the same receptor. The rate and duration of tolerance specific to 25D-NBOMe have not been measured.

Dependence liability is uncertain. Classical psychedelics generally carry low dependence risk, but 25D-NBOMe's dopaminergic reward-circuit activation sets it apart. Rodent studies confirmed reinforcing properties — rats self-administered the compound and showed conditioned place preference, with dopamine changes in the nucleus accumbens as the underlying mechanism.^[4] Whether this translates to human dependence is unknown. safety citation needed No physical withdrawal has been documented for any NBOMe compound.

Drug interactions

The interaction profile of 25D-NBOMe has not been systematically studied. All assessments below are based on pharmacological mechanisms and class-level inference. inferred

Tramadol is classified as dangerous. Tramadol's serotonergic activity creates serotonin syndrome risk, and its seizure-lowering properties combine additively with the seizure risk already carried by NBOMe compounds at high doses.^[17]

Cocaine is classified as dangerous. Both compounds constrict blood vessels, and both carry independent heart toxicity risk — 25D-NBOMe through hERG channel inhibition,^[6] cocaine through sodium channel blockade and catecholamine-driven cardiac stress.^[17]

MDMA presents serotonin syndrome risk through its mechanism of flooding the synapse with serotonin. safety citation needed

Lithium combined with serotonergic psychedelics carries documented seizure risk in the class literature and should be considered potentially dangerous. safety citation needed

Cannabis interaction is uncharacterized. No specific data exist for this combination.

Contraindications

No substance-specific contraindication data have been published. The following are derived from pharmacological profile and class-level safety data.

Absolute contraindications:

• Pre-existing heart rhythm abnormalities or prolonged QT interval: hERG channel inhibition^[6] creates direct risk of fatal arrhythmia
• QT-prolonging medications: Certain heart medications, antipsychotics, and antibiotics — additive QT prolongation risk safety citation needed
• Seizure disorders: NBOMe compounds lower seizure threshold at high doses^[8]
• Serotonergic medications: MAOIs, SSRIs, SNRIs, tramadol — serotonin syndrome risk

Relative contraindications:

• Cardiovascular disease: Sympathomimetic effects stress the heart and blood vessels
• Electrolyte imbalances: Low potassium and magnesium increase susceptibility to heart rhythm problems
• Liver impairment: Predicted reliance on liver metabolism suggests impaired clearance inferred
• Psychiatric conditions: History of psychotic disorders — class-level risk of triggering psychotic episodes

25D-NBOMe occupies a complex legal position internationally. Unlike its more widely encountered analogs (25I-NBOMe, 25B-NBOMe, 25C-NBOMe), it has not been specifically named in most scheduling actions, instead falling under analog provisions, blanket bans, or structural catch-all definitions.

Analog act considerations

In the United States, 25D-NBOMe's structural and pharmacological similarity to the Schedule I NBOMe compounds makes it subject to the Federal Analogue Act when intended for human consumption. Prosecution requires demonstrating both substantial structural similarity and substantially similar pharmacological effect — a standard that 25D-NBOMe meets by published receptor data.^[1] Enforcement involves case-by-case judicial determination rather than categorical scheduling.